Canadian Immunodeficiency Research Collaborative Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2006
NCT00334022
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

raltegravir (isentress) (1 trial)

Drugs in Other Trials (1)

enfuvirtide (fuzeon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

HIV Infections (Phase 2)

Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2